/
GKOS
$139.76-$2.43 (-1.71%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$8.5B
59M shares
52-week range
$73.16 – $148.11
89% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NYSE
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$55.53
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $181.3M | $237.0M | $225.0M | $294.0M | $282.9M | $314.7M | $383.5M | $507.4M |
| Cost of revenue | $25.1M | $38.6M | $91.7M | $66.6M | $69.0M | $75.6M | $94.0M | $114.2M |
| Gross profit | $156.2M | $198.4M | $133.2M | $227.4M | $213.9M | $239.1M | $289.5M | $393.2M |
| Gross margin | 86.2% | 83.7% | 59.2% | 77.3% | 75.6% | 76.0% | 75.5% | 77.5% |
| R&D | $49.7M | $68.3M | $85.4M | $101.0M | $123.3M | $138.8M | $136.4M | $150.6M |
| Operating income | −$13.0M | −$50.3M | −$123.6M | −$32.9M | −$82.3M | −$128.7M | −$122.4M | −$86.7M |
| EBITDA | −$6.1M | −$37.6M | −$83.6M | −$1.5M | −$48.8M | −$82.1M | −$95.6M | −$146.1M |
| Net income | −$13.0M | $15.4M | −$120.3M | −$49.6M | −$99.2M | −$134.7M | −$146.4M | −$187.7M |
| Net margin | -7.1% | 6.5% | -53.5% | -16.9% | -35.1% | -42.8% | -38.2% | -37.0% |
| EPS (diluted) | -0.37 | 0.37 | -2.70 | -1.07 | -2.09 | -2.78 | -2.77 | -3.28 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $631M | $-0.51 | $-0.60–$-0.35 | 8 |
| 2027 | $796M | $0.44 | $0.13–$0.60 | 9 |
| 2028 | $1.0B | $1.52 | $0.82–$2.36 | 8 |
| 2029 | $1.3B | $2.73 | $2.62–$2.82 | 6 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
www.glaukos.com- Employees
- 1,094
- IPO / List date
- Jun 25, 2015
- HQ
- ALISO VIEJO, CA
Held by traders on TradeandTell
No one on the platform currently holds GKOS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 118,892 | $12.8M |
| Bridgewater Associatesas of 2025-03-31 | 2,356 | $231.9K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded GKOS yet.
